Market News & Trends
Sanofi & Alnylam Enter Into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Sanofi and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and…
Enable Injections Achieves ISO Certification to Meet Mounting Demand for Drug Delivery Device Combination Products
Enable Injections, Inc., developer of the advanced enFuse large volume wearable injectors (LVWI) platform for subcutaneous delivery of biologics, has been awarded the International Organization…
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody
BeiGene, Ltd. recently announced that in December 2017, the first patient was dosed in a global Phase 3 clinical trial of tislelizumab, an investigational anti-PD-1…
Bellerophon Announces First Patient Enrolled in Phase 2b Study
Bellerophon Therapeutics, Inc. recently announced the first patient has been randomized into a Phase 2b study evaluating INOpulse in patients with Pulmonary Hypertension associated with…
Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies
Atara Biotherapeutics, Inc. recently announced initiation of two Phase 3 clinical studies to evaluate tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus…
GeoVax & Vaxeal to Collaborate on Cancer Immunotherapy Program
GeoVax Labs, Inc. recently announced it is collaborating with Vaxeal Holding SA on the expansion of GeoVax’s cancer immunotherapy program. GeoVax’s immuno-oncology program is based…
Inovio Enters License & Collaboration Agreement With ApolloBio
Inovio Pharmaceuticals, Inc. recently announced it entered an amended agreement providing ApolloBio Corporation with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy…
Secondary Packaging – How “One-Stop-Shop” Solutions Can Help Address a Changing World
By: Daniela Geiger, Vetter, Product & Service Manager In a rapidly aging world, it could be difficult for today’s pharmaceutical and biotechnology companies to…
Platform Technology Company Cell Design Labs to be Acquired by Gilead
Cell Design Labs, Inc. recently announced that Gilead Sciences has agreed to acquire them in a structured buy out valued for up to $567 million,…
AMRI Doubles Bulk API Aseptic Manufacturing Capacity
AMRI, a global contract research, development, and manufacturing organization, has more than doubled its current bulk Active Pharmaceutical Ingredient (API) aseptic manufacturing capacity. The addition…
MonoSol Rx Changes Name, Expands CNS Portfolio
MonoSol Rx recently announced the change of its corporate name to Aquestive Therapeutics. The new name reflects the company's expanded capabilities in developing and commercializing…
Carrick Therapeutics Announces First Patient Dosed in Phase I Clinical Trial
Carrick Therapeutics recently announced that the first patient has been dosed in the Phase 1 clinical program of CT7001 - an orally bioavailable Cyclin-dependent Kinase…
LAM Therapeutics Announces Progress of its Clinical Portfolio With FDA Clearance
LAM Therapeutics, a 4Catalyzer company, advanced its clinical portfolio with the US FDA clearance of LAM’s Investigational New Drug (IND) application for LAM-003 in leukemia patients.…
NRGene & Tel Aviv Sourasky Medical Center Collaborate on Parkinson’s Genomes
NRGene, the worldwide leader in genomic assembly and analysis, has partnered with the Genetic Institute of Tel Aviv Sourasky Medical Center (TASMC) to perform genomic…
RespireRx Pharmaceuticals Announces Publication of Phase 2B PACE Study
RespireRx Pharmaceuticals Inc. recently announced that the results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) clinical trial have been published by the principal…
Do's & Don'ts for Orphan Drug Support Programs
Getting personal with rare disease patients. By: Nancy Pilcher, RN, Director, Business Development, AmerisourceBergen Complex. It’s the word most often associated with the…
Inovio’s Cancer Immunotherapy Combined With Checkpoint Inhibitor Synergistically Shrinks Tumor & Improves Survival
Inovio Pharmaceuticals, Inc. demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical tumor…
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial
Sevion Therapeutics, Inc. and Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel translational read-through inducing drugs (TRIDs) for genetic diseases caused by nonsense mutations,…
PhaseBio Enters Worldwide License Agreement With MedImmune
PhaseBio Pharmaceuticals, Inc. recently announced it has entered an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for…
TGR-1202 Selected as the PI3K Delta Inhibitor to be Used in Multiple-Arm Comparison Study
TG Therapeutics recently announced that along with SWOG, the global cancer clinical trials group funded by the National Cancer Institute (NCI), it has initiated a…
